Evaluating the Cost-effectiveness of Pharmaceuticals in Canada
Canada adopted guidelines for the economic evaluation of pharmaceuticals in 1994, and a central process for drug assessment in 2003. The context and the way the issue reached the agenda in the two time periods differed. The guidelines were adopted amidst growing academic interest in methods for econ...
Main Author: | Katherine Boothe |
---|---|
Format: | Article |
Language: | English |
Published: |
McMaster University Library Press
2016-03-01
|
Series: | Health Reform Observer - Observatoire des Réformes de Santé |
Subjects: | |
Online Access: | https://mulpress.mcmaster.ca/hro-ors/article/view/2796/2561 |
Similar Items
-
Healthcare failure mode and effects analysis and cost‑minimization analysis of three pharmaceutical services
by: Álvaro Caballero-Romero, et al.
Published: (2021-03-01) -
Cost-consequence analysis of Pharmaceutical Care program for systemic arterial hypertension in the public health system in Brazil
by: Maurílio de Souza Cazarim, et al.
Published: (2018-02-01) -
Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status
by: N. Maniadakis, et al.
Published: (2017-05-01) -
Paying for cost-effective health care: Does it violate both static- and dynamic efficiency?
by: Tomas J Philipson
Published: (2015-03-01) -
Pharmaceutical companies’ views on a health technology assessment (HTA) entity in Saudi Arabia
by: Hussain Abdulrahman Al-Omar, et al.
Published: (2020-06-01)